Expertise in
7
conditions

Dr. Robert L. Findling

Child and Adolescent Psychiatry
Virginia Treatment Center For Children (Vtcc)-Inpatient
1308 Sherwood Ave, 
Richmond, VA 
Accepting New Patients
Offers Telehealth
Expertise in
7
conditions
Virginia Treatment Center For Children (Vtcc)-Inpatient
1308 Sherwood Ave, 
Richmond, VA 

Overview

Robert Findling is a Child and Adolescent Psychiatrist practicing medicine in Richmond, Virginia.

Dr. Findling is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), Cyclothymic Disorder, and Schizophrenia.

He is actively involved in clinical research, co-authoring 283 peer reviewed articles and participating in 8 clinical trials. Dr. Findling is currently accepting new patients.

Specialties

Child and Adolescent Psychiatry

Licenses

Child & Adolescent Psychiatry in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Piedmont
  • HMO
  • POS
View 2 Less Insurance Carriers -

Locations

Virginia Treatment Center For Children (Vtcc)-Inpatient
1308 Sherwood Ave, Richmond, VA 23220

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents
Enrollment Status: Terminated
Publish Date: May 09, 2024
Intervention Type: Drug
Study Drug: NaBen®
Study Phase: Phase 2/Phase 3
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder
Enrollment Status: Terminated
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drug: Carbamazepine
Study Phase: Phase 4
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase III, Open-Label, Extension, Multi-Center, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: June 08, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: March 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: August 14, 2020
Intervention Type: Device
Study Phase: Not Applicable
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects
Enrollment Status: Completed
Publish Date: December 19, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 7 Less Clinical Trials

283 Total Publications

Symptoms of cognitive disengagement syndrome in youth diagnosed with ADHD, mood disorders, and comorbid presentations.
Symptoms of cognitive disengagement syndrome in youth diagnosed with ADHD, mood disorders, and comorbid presentations.
Journal: Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence
Published: August 07, 2026
Similar Doctors
Expertise in
8
conditions
Dr. Craig W. Swainey
Child and Adolescent Psychiatry | Oncology | Psychiatry
Expertise in
8
conditions
Dr. Craig W. Swainey
Child and Adolescent Psychiatry | Oncology | Psychiatry
Referral may be required

Henrico Area Mental Heatlh And Developmental Services

10299 Woodman Rd, 
Glen Allen, VA 
 (6.2 miles away)
804-727-8500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Craig Swainey is a Child and Adolescent Psychiatrist and an Oncologist practicing medicine in Glen Allen, Virginia. Dr. Swainey is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Familial Pancreatic Cancer, Pancreatic Cancer, Essential Thrombocythemia, and Paget Disease of the Breast. Dr. Swainey is currently accepting new patients.

Expertise in
10
conditions
Dr. Harpreet Reeba
Child and Adolescent Psychiatry
Expertise in
10
conditions
Dr. Harpreet Reeba
Child and Adolescent Psychiatry
Referral may be required

Office

13901 Coalfield Commons Pl Ste 102, 
Midlothian, VA 
 (12.9 miles away)
804-378-0800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Harpreet Reeba is a Child and Adolescent Psychiatrist practicing medicine in Midlothian, Virginia. Dr. Reeba is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Schizoaffective Disorder, Major Depression, Seasonal Affective Disorder (SAD), and Bipolar Disorder (BPD). Dr. Reeba is currently accepting new patients.

Expertise in
6
conditions
Dr. David G. Iii
Child and Adolescent Psychiatry
Expertise in
6
conditions
Dr. David G. Iii
Child and Adolescent Psychiatry
Referral may be required

Office

1000 Boulders Pkwy Ste 202, 
North Chesterfield, VA 
 (4.9 miles away)
804-320-7881
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Iii is a Child and Adolescent Psychiatrist practicing medicine in North Chesterfield, Virginia. Dr. Iii is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Obsessive-Compulsive Disorder (OCD), Childhood Disintegrative Disorder, Generalized Anxiety Disorder (GAD), and Insomnia. Dr. Iii is currently accepting new patients.

Frequently Asked Questions about Dr. Robert L. Findling

How do I make an appointment with Dr. Robert L. Findling?

You can book an appointment with Dr. Robert L. Findling by calling their office at 804-828-2000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert L. Findling a top-rated expert for Attention Deficit Hyperactivity Disorder (ADHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert L. Findling is classified as an Elite expert for Attention Deficit Hyperactivity Disorder (ADHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert L. Findling specialize in?

While Dr. Robert L. Findling is a Child and Adolescent Psychiatry, they have specific expertise in Attention Deficit Hyperactivity Disorder (ADHD), Bipolar Disorder (BPD), and Cyclothymic Disorder. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Child and Adolescent Psychiatry.

Does Dr. Robert L. Findling participate in research or clinical trials?

Yes. Dr. Robert L. Findling has published 283 articles and abstracts on conditions like Attention Deficit Hyperactivity Disorder (ADHD). You can view a list of Dr. Robert L. Findling's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert L. Findling accept my insurance?

Dr. Robert L. Findling accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-828-2000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Findling's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile